Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in renal transplantation between 1990 and 2002 in Spain

Angel Alonso Hernández, Francesc Moreso, Beatriz Bayés, Ricardo Lauzurica, Dámaso Sánz-Guajardo, Ernesto Gómez-Huertas, Porfirio Pereira, Javier Paul, Josep Crespo, Juan J Amenábar, Juan Oliver, Daniel Serón, Angel Alonso Hernández, Francesc Moreso, Beatriz Bayés, Ricardo Lauzurica, Dámaso Sánz-Guajardo, Ernesto Gómez-Huertas, Porfirio Pereira, Javier Paul, Josep Crespo, Juan J Amenábar, Juan Oliver, Daniel Serón

Abstract

Background. Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type 1 receptor blockers (ARB) decrease cardiovascular mortality and slow the progression of renal disease in non-transplant patients, but their impact on kidney transplant outcome has not been well established.Methods. Patients receiving a renal allograft in Spain in 1990, 1994, 1998 and 2002 were considered for the present study. Only adult (>/=18 years) recipients of a single kidney transplant functioning at the end of the first year were considered. A total of 4842 patients with clinical data about ACEI/ARB therapy were included.Results. During the initial 2 years after transplant, ACEI/ARB were less frequently used in the 1990 and 1994 cohorts than in 1998 and 2002 (15.1%, 24.6%, 33.5% and 45.1%, respectively; P < 0.001). During the first year, a total of 1063 patients (22.8%) received ACEI/ARB treatment, and graft survival (50.0% for treated patients and 51.4% for untreated, P = ns), death-censored graft survival (60.6% versus 63.5%, P = ns) and patient survival (68.8% versus 66.6%, P = ns) were not different. During the initial 2 years, 1472 patients (31.4%) received treatment with ACEI/ARB, and graft survival tended to be higher in treated patients (54.4% and 50.9%, P = 0.063). Since there was an interaction between ACEI/ARB treatment and year of transplant, graft survival was analysed in each cohort. Cox regression analysis including the propensity score for ACEI/ARB treatment showed an association between ACEI/ARB treatment and graft survival in the 2002 cohort (relative risk 0.36 and 95% confidence interval 0.17-0.75, P = 0.007). Death-censored graft survival (63.8% versus 63.1%, P = ns) and patient survival (68.1% and 66.5%, P = ns) were not significantly different.Conclusions. The use of ACEI/ARB during the initial 2 years after transplantation was associated with a better graft survival, but this effect was only observed in the 2002 cohort.

References

    1. Brenner BM, Cooper ME, de Zeeuw, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
    1. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462.
    1. Cohen DL, Townsend RR. Is there value to adding ARB to ACE inhibitors in the management of CKD? J Am Soc Nephrol. 2009;20:1666–1668.
    1. Hiremath S, Fergusson D, Doucette S, et al. Renin-angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant. 2007;7:2350–2360.
    1. El-Agroudy AE, Hassan NA, Foda MA, et al. Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol. 2003;23:300–306.
    1. Artz MA, Hilbrands LB, Borm G, et al. Blockade of the renin–angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant. 2004;19:2852–2857.
    1. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol. 2006;17:889–899.
    1. Zaltzmam JS, Nash M, Chiu R, et al. The benefits of renin–angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol Dial Transplant. 2004;19:940–944.
    1. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol. 2006;17:3257–3262.
    1. Palmer BF. Managing hyperkalemia caused by inhibitors of the rennin–angiotensin–aldosterone system. N Engl J Med. 2004;351:585–592.
    1. Karthikeyan V, Karpinski J, Nair RC, et al. The burden of chronic kidney disease in renal transplant recipients. Am J Transplant. 2004;4:262–269.
    1. Wormer KL, Vella JP, Sayegh MH, et al. Chronic allograft dysfunction: mechanisms and new approaches to therapy. Semin Nephrol. 2000;20:126–147.
    1. Seron D, Moreso F, Grinyo JM. Prevention and management of late renal allograft dysfunction. J Nephrol. 2001;14:71–79.
    1. Stigant CE, Cohen J, Vivera BS, et al. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am J Kidney Dis. 2000;35:58–63.
    1. Lin J, Valeri A, Markowitz GS, et al. Angiotensin-converting enzyme inhibition in chronic allograft nephropathy. Transplantation. 2002;73:783–788.
    1. Tutone VK, Mark PB, Stewart GA, et al. Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant. 2005;19:181–192.
    1. Amara AB, Sharma A, Alexander JL, et al. Randomized controlled trial: lisinopril reduces proteinuria, ammonia, and renal polypeptide tubular catabolism in patients with chronic allograft nephropathy. Transplantation. 2010;89:104–114.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe